Gilead Signs US$1.7 B Deal with MacroGenics for Bispecific Antibodies
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 10 (Table of Contents)
Published: 20 Oct-2022
DOI: 10.3833/pdr.v2022.i10.2737 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In an attempt to strengthen its immuno-oncology pipeline, Gilead Sciences has entered into a collaboration agreement with MacroGenics to develop bispecific antibodies...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS